1. Tsai CM, Chang KT, Li L, Perng RP, Yang LY. Interrelationships between cellular nucleotide excision repair, cisplatin, cytotoxicity, HER-2/neu gene expression, and epidermal growth factor receptor level in non-small cell lung cancer cells. Jpn J Cancer Res 2000; 91(2): 213-22.
2. Lai CL, Tsai CM (correspondence), Tsai TT, Kuo BI, Chang KT, Fu HT, Perng RP, Chen JY. Presence of serum anti-p53 antibodies is associated with pleural effusion and poor prognosis in lung cancer patients. Clin Cancer Res 1998; 4(12): 3025-30.
3. Tsai CM, Levitzki A, Wu LH, Chang KT, Cheng CC, Gazit A, Perng RP. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185neu expressing non-small cell lung cancer cells. Cancer Res 1996; 56(5):1068-74.
4. Tsai CM, Chang KT, Chen JY, Chen YM, Chen MH, Perng RP. Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu. Cancer Res 1996; 56(4):794-801.
5. Tsai CM, Chang KT, Wu LH, Chen JY, Gazdar AF, Chen MH, Perng RP. Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines. Cancer Res 1996; 56:206-9.

1. Chiang CH, Wu K,Yu CP, Perng WC, Yan HC, Wu CP, Chang DM. Protective agents used as additives to promote the protection of ischemia-Reperfutioin in university of wisconsin solution (UW). Clinical Science1998; 95:　p369-376.
2. Chiang CH, Wu K,Yu CP, Yan HC, Perng WC, Wu CP. Hypothermia and prostaglandin E1 produce synergistic attenuation of ischemia-reperfusion lung injury Am. J. Respir. Crit. Care. Med. 1999; 160:1319-1323
3. Chiang CH, Wu CP, Perng WC, Yan HC, ,Yu CP. TNF-α antibody or 3-deazaadenosine as additives to promote protection by UW solution in I/R injury. Clinical Science 2000; 99: 215-222..
4. Chiang CH, Wu CP, Perng WC, Yan HC. Yu CP. Dexamethasone and pentastarch produce synergistic attenuation on ischemia-reperfusion lung injury. Clinical Science. 2000; 99:413-419.
5. Chiang CH,Yu CP,Yan HC,Perng WC,Wu CP. Cytokine upregulation in ischemia-reperfused lungs perfused with University of Wisconsin solution and normal saline. Clinical Science 2001; 101:285-294.

1. Lee YC, Chang SC, Chern JH, et al. Sialyl Lewis X-i antigen in pleural effusion. (letter) Chest 1999; 116(2): 582-3.
2. Lee YC, Chern JH, Pen CC, et al. Argyrophilic nucleolar organizer regions in cells of thymoma and thymic carcinoma: Correlation with DNA ploidy and clinicopathologic characteristics. Chest 1999; 115(4): 1115-9.
3. Lee YC, Chern JH, Lai SL, et al. Sialyl stage-specific embryonic antigen-1: A useful marker for differentiating the etiology of pleural effusion. Chest 1998; 114(6): 1542-5.
4. Lee YC, Chern JH, Li WY, et al. AgNORs in lung cancer: Correlation with DNA ploidy and degree of differentiation. Anal Quant Cytol Histol 1997; 19(3)271-6.

陳重華醫師　　Chung-Hwa Chen, M.D. 　　民國43年生　　男
學位：	高雄醫學院醫學系
進修：	美國猶太醫學中心內科
現職：	新竹東元醫院教學副院長
教職：	國立陽明大學醫學系內科學科兼任副教授
經歷：	新竹東元醫院內科主任 台北榮民總醫院胸腔部主治醫師 振興復健中心胸腔及呼吸治療科主任 台北市市立中興醫院內科部主任
專科學會：	中華民國內科醫學會 中華民國胸腔醫學會 中華民國感染症醫學會 中華民國環境職業醫學會
通訊處：	新竹東元醫院
代表著作：

1. Chen CH, Tsai JJ, Shih JF, Perng RP. Tubberculous subcutaneous abscesses developing during chemotherapy for pulmonary tuberculosis. Scand J infect Dis 1993;25:149-52
2. Chen CH, Yang MH, Lin JS, Lee YC, Perng RP. The in-vitro activity of beta-lactamase inhibitors in combination with cephalosporins against M. tuberculosis. Proceedings of the national Science Council, ROC, Par B: life sciences 1995;19:80-4
3. Chen CH, Shih JF, Wang LS, Perng RP. Tubercculous subcutaneous abscess-an analysis of 7 cases. Tuberecle and lung Dis 1996;77:184-7
4. Chen CH, Lai CL, Chiu MH, Liu RD, Shih JF, Lee YC, Perng RP. Diagnostic value of ultrasonically guided lung aspiration in pneumonia. J Formos Med Associ 1995;94:s137-43
5. Chen CH, Lai CL, Perng RP. Foreign body aspiration into lower airway in Chinese adults. Chest 1997;112:129-33.

1. Yuh-Min Chen, Reury-Perng Perng, Jen-Fu Shih, Yu-Chin Lee, Chia-San Lee, Chun-Ming Tsai, Jacqueline Whang-Peng. A Randomized Phase II Study of Weekly Paclitaxel or Vinorelbine in Combination with Cisplatin Against Inoperable Non-small-cell Lung Cancer Previously Untreated. British Journal of Cancer 2004 (in print)
2. Yuh-Min Chen, Reury-Perng Perng, Mei-Chun Chen, Chun-Ming Tsai, Jacqueline Ming-Liu, Jacqueline Whang-Peng. A Phase II Trial of Vinorelbine plus Gemcitabine in Previously Untreated Inoperable (Stage IIIb/IV) Non-Small Cell Lung Cancer Patients Aged 80 or Older. Lung Cancer 2003; 40: 221-6.
3. Yuh-Min Chen, Jen-Fu Shih, Chia-San Lee, Mei-Chun Chen, Wei-Chun Lin, Chun-Ming Tsai, Reury-Perng Perng. Phase II Study of Docetaxel and Ifosfamide Combination Chemotherapy in Non-Small-Cell Lung Cancer Patients Failing Previous Chemotherapy Containing Paclitaxel or not. Lung Cancer 2003; 39: 209-14.
4. Yuh-Min Chen. Paclitaxel plus gemcitabine may be as active and well tolerated as paclitaxel plus carboplatin for advanced non-small-cell lung cancer. Cancer Treatment Reviews 2003; 29: 69-71.
5. Yuh-Min Chen, Reury-Perng Perng, Yu-Chin Lee, Jen-Fu Shih, Chia-San Lee, Chun-Ming Tsai, Jacqueline Whang-Peng. Paclitaxel Plus Carboplatin, Compared to Paclitaxel plus Gemcitabine, Shows Equal Efficacy While More Cost-Effectiveness - A Randomized Study of Combination Chemotherapy Against Inoperable Non-small-Cell Lung Cancer Previously Untreated. Annals of Oncology 2002; 13: 108-15.